Jubilant Life Sciences is currently the top loser on the BSE, down 10% at Rs.149.10 and this is after hitting the day’s low point at Rs.144. Volumes have jumped up over 7 times.

The stock has slumped after its consolidated net losses for Q2FY15 rose to Rs.94 crore, up from Rs.81 crore loss in Q2FY14. This loss, the company has explained was mainly on account of continued impact of US FDA Warning letter on Spokane facility and adverse price impact on account of new capacities and regulatory changes in China in Advanced Intermediates business. And for H1FY15, consolidated net loss was at Rs.89 crore, lesser than the loss of Rs.133 crore in previous H1.

Revenues from pharmaceuticals was Rs.614 crore, down 11% and life science ingredients segment was Rs.757 crore, up 2%. International revenues, at Rs.955 crore, contributed 70% to the overall mix.